28150-30-3 Usage
Description
[[P-(Benzyloxy)phenoxy]methyl]oxirane, also known as 2-[[4-(Phenylmethoxy)phenoxy]methyl]-oxirane, is an organic compound that serves as a reagent in the synthesis of various adrenergic agents. It is characterized by its oxirane ring and benzyloxyphenoxy functional groups, which contribute to its reactivity and utility in chemical reactions.
Uses
Used in Pharmaceutical Industry:
[[P-(Benzyloxy)phenoxy]methyl]oxirane is used as a reagent for the preparation of adrenergic agents, which are crucial in the treatment of various medical conditions. These agents include beta-adrenergic blocking agents, β1-adrenoceptor ligands, and β-adrenergic agonists. [[p-(benzyloxy)phenoxy]methyl]oxirane plays a vital role in the development of these drugs due to its ability to facilitate the synthesis process and improve the overall effectiveness of the final products.
In the synthesis of beta-adrenergic blocking agents, [[p-(benzyloxy)phenoxy]methyl]oxirane is used to create compounds that can effectively block the action of adrenaline and noradrenaline, thus helping to lower blood pressure and reduce the workload on the heart. This application is particularly useful in the treatment of hypertension, angina, and certain arrhythmias.
As a reagent for the preparation of β1-adrenoceptor ligands, [[p-(benzyloxy)phenoxy]methyl]oxirane contributes to the development of drugs that selectively target the β1-adrenergic receptors. These ligands are essential in the treatment of conditions such as chronic obstructive pulmonary disease (COPD) and heart failure, where selective targeting of β1-receptors can provide more precise and effective therapy.
In the synthesis of β-adrenergic agonists, [[p-(benzyloxy)phenoxy]methyl]oxirane is used to create compounds that can stimulate the adrenergic receptors, leading to an increase in heart rate, blood pressure, and bronchodilation. These agonists are commonly used in the treatment of asthma, chronic obstructive pulmonary disease (COPD), and certain cardiovascular conditions.
Overall, [[p-(benzyloxy)phenoxy]methyl]oxirane plays a significant role in the pharmaceutical industry, particularly in the development and synthesis of adrenergic agents that are essential for the treatment of various medical conditions. Its unique chemical properties and reactivity make it a valuable compound in the ongoing research and development of new and improved drugs.
Check Digit Verification of cas no
The CAS Registry Mumber 28150-30-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,8,1,5 and 0 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 28150-30:
(7*2)+(6*8)+(5*1)+(4*5)+(3*0)+(2*3)+(1*0)=93
93 % 10 = 3
So 28150-30-3 is a valid CAS Registry Number.
InChI:InChI=1/C16H16O3/c1-2-4-13(5-3-1)10-17-14-6-8-15(9-7-14)18-11-16-12-19-16/h1-9,16H,10-12H2
28150-30-3Relevant articles and documents
6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases
Thompson, Andrew M.,Blaser, Adrian,Palmer, Brian D.,Anderson, Robert F.,Shinde, Sujata S.,Launay, Delphine,Chatelain, Eric,Maes, Louis,Franzblau, Scott G.,Wan, Baojie,Wang, Yuehong,Ma, Zhenkun,Denny, William A.
, p. 2583 - 2589 (2017/05/10)
As part of a quest for backups to the antitubercular drug pretomanid (PA-824), we investigated the unexplored 6-nitro-2,3-dihydroimidazo[2,1-b][1,3]-thiazoles and related -oxazoles. The nitroimidazothiazoles were prepared in high yield from 2-bromo-4-nitroimidazole via heating with substituted thiiranes and diisopropylethylamine. Equivalent examples of these two structural classes provided broadly comparable MICs, with 2-methyl substitution and extended aryloxymethyl side chains preferred; albeit, S-oxidised thiazoles were ineffective for tuberculosis. Favourable microsomal stability data for a biaryl thiazole (45) led to its assessment in an acute Mycobacterium tuberculosis mouse model, alongside the corresponding oxazole (48), but the latter proved to be more efficacious. In vitro screening against kinetoplastid diseases revealed that nitroimidazothiazoles were inactive versus leishmaniasis but showed interesting activity, superior to that of the nitroimidazooxazoles, against Chagas disease. Overall, “thio-delamanid” (49) is regarded as the best lead.
NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES
-
Page/Page column 10, (2011/02/25)
The current invention pertains to nitroimidazooxazine and nitroimidazooxazole analogues, their methods of preparation, and uses of the compounds as treatment for Mycobacterium tuberculosis, for use as anti-tubercular drugs, for use as anti-protozoal agents with unexpectedly high potency against Trypanosoma cruzi or Leishmania donovani, and for the treatment of other microbial infections.
LTA4H modulators and uses thereof
-
Page/Page column 41, (2008/12/07)
Leukotriene A4 hydrolase (LTA4H) inhibitors, compositions containing them, and methods of use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated with inflammation.
